Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

FGFR2 inhibitor

DRUG CLASS:

FGFR2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	RLY-4008 Sensitive: C2 – Inclusion Criteria RLY-4008 Sensitive : C2	RLY-4008 Sensitive: C2 – Inclusion Criteria RLY-4008 Sensitive : C2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	RLY-4008 Sensitive: C3 – Early Trials RLY-4008 Sensitive : C3	RLY-4008 Sensitive: C3 – Early Trials RLY-4008 Sensitive : C3
FGFR2-ARHGAP24 fusion	Cholangiocarcinoma	FGFR2-ARHGAP24 fusion	Cholangiocarcinoma	TT-00434 Sensitive: C3 – Early Trials TT-00434 Sensitive : C3	TT-00434 Sensitive: C3 – Early Trials TT-00434 Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D
FGFR2 N549K	Endometrial Cancer	FGFR2 N549K	Endometrial Cancer	RLY-4008 Sensitive: D – Preclinical RLY-4008 Sensitive : D	RLY-4008 Sensitive: D – Preclinical RLY-4008 Sensitive : D